Application of diffusion-edited NMR spectroscopy for the structural characterization of drug metabolites in mixtures

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 1, 2010, Pages 164-169

  Khera, Smriti ^a   Grillo, Mark ^a   Schnier, Paul ^a   Hollis, Steve ^a  

^a AMGEN INC   (United States)

Author keywords

Diffusion edited spectroscopy; DOSY; Ethacrynic acid; Mefenamic acid; Metabolite identification; Solvent suppression

Indexed keywords

DRUG METABOLITE; ETACRYNIC ACID; ETACRYNIC ACID GLUTATHIONE THIOETHER; MEFENAMIC ACID; MEFENAMIC ACID GLUTATHIONE THIOESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; DRUG STRUCTURE; INTERMETHOD COMPARISON; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SIGNAL NOISE RATIO;

ANIMALS; BILE; BILE ACIDS AND SALTS; DIFFUSION; ETHACRYNIC ACID; GLUTATHIONE; MAGNETIC RESONANCE SPECTROSCOPY; MEFENAMIC ACID; RATS; SOLVENTS;

EID: 70349319383     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.07.010     Document Type: Article

References (17)

1. Kalgutkar A.S., Gardner I., Obach R.S., Shaffer C.L., Callegari E., Henne K.R., Mutlib A.E., Dalvie D.K., Lee J.S., Nakai Y., O'Donnell J.P., Boer J., and Harriman S.P. Curr. Drug Metab. 6 (2005) 161-225
2. Samuel K., Yin W., Stearns R.A., Tang Y.S., Chaudhary A.G., Jewell J.P., Lanza Jr. T., Lin L.S., Hagmann W.K., Evans D.C., and Kumar S. J. Mass Spectrom. 38 (2003) 211-221
3. Matsuki Y., Dan J., Fukuhara K., Ito T., and Nambara T. Chem. Pharm. Bull. 36 (1988) 1431-1436
4. Chen Q., Doss G.A., Tung E.C., Liu W., Tang Y.S., Braun M.P., Didolkar V., Strauss J.R., Wang R.W., Stearns R.A., Evans D.C., Baillie T.A., and Tang W. Drug Metab. Dispos. 34 (2006) 145-151
5. Huang X., Powers R., Tymiak A., Espina R., and Roongta V. Introduction to NMR and its application in metabolite structure determination. In: Zhang D., Zhu M., and Humphreys W.G. (Eds). Drug Metabolism in Drug Design and Development (2008), John Wiley & Sons Inc., Hoboken 369-409
6. Stilbs P. Progr. Nucl. Magn. Reson. Spectrosc. 19 (1987) 1-45
7. Price W.S. Annu. Rep. NMR Spectrosc. 38 (1999) 289-354
8. van Zijl P.C.M., and Moonen C.T.W. J. Magn. Reson. 87 (1990) 18-25
9. Esturau N., and Espinosa J.F. J. Org. Chem. 71 (2006) 4103-4110
10. Giernoth R., and Bankmann D. Eur. J. Org. Chem. 2005 (2005) 4529-4532
11. Bradamante S., Barenghi L., Beretta G., Bonfa M., Rollini M., and Manzoni M. Biotechnol. Bioeng. 80 (2002) 589-593
12. Klaassen C.D., and Fitzgerald T.J. J. Pharmacol. Exp. Ther. 191 (1974) 548-552
13. van Iersel M.L.P.S., van Lipzig M.M.H., Rietjens I.M.C.M., Vervoort J., and van Bladeren P.J. FEBS Lett. 441 (1998) 153-157
14. Lo W.-J., Chiou Y.-C., Hsu Y.-T., Lam W.S., Chang M.-Y., Jao S.-C., and Li W.-S. Bioconjug. Chem. 18 (2007) 109-120
15. Zheng J., Ma L., Xin B., Olah T., Humphreys W.G., and Zhu M. Chem. Res. Toxicol. 20 (2007) 757-766
16. Grillo M.P., and Benet L.Z. Drug Metab. Dispos. 30 (2002) 55-62
17. Kang P., Dalvie D., Smith E., Zhou S., and Deese A. Drug Metab. Dispos. 35 (2007) 1081-1088